论文部分内容阅读
目的研究甲氨喋呤(MTX)联用卡介苗多糖核酸(BCG-PSN)治疗激素依赖型哮喘的疗效和安全性。方法将68例激素依赖型哮喘随机分为治疗组和对照组,治疗组给予MTX、BChG-PSN;对照组单用MTX,治疗期均为3个月。记录试验前、后患者的临床症状评分、PEF、FEV1、强的松每日用量。检测药物不良反应。结果两组临床症状评分、强的松日用量均较治疗前有显著减少(P<0.05),治疗组的减少更为明显,且与对照组相比,差异具有显著性(P<0.05);治疗组治疗后PEF、FEV1较治疗前明显增加(P<0.05),对照组治疗后PEF、FEV1无显著性改变(P>0.05);两组治疗过程中均未发现严重的不良反应,不良反应发生率两组无差别(P>0.05),但对照组有2例患者发生呼吸道感染。结论MTX联用BCG-PSN治疗激素依赖型哮喘疗效可靠,不良反应少,优于单用MTX,是一种安全有效的治疗方案。
Objective To investigate the efficacy and safety of methotrexate (MTX) combined with BCG-PSN in the treatment of hormone-dependent asthma. Methods 68 cases of hormone-dependent asthma were randomly divided into treatment group and control group, the treatment group was given MTX, BChG-PSN; control group MTX alone, the treatment period was 3 months. The clinical symptom score, PEF, FEV1, prednisone daily dosage were recorded before and after the trial. Detection of adverse drug reactions. Results The scores of clinical symptoms and the daily dosage of prednisone in both groups were significantly lower than those before treatment (P <0.05), and the reduction in the treatment group was more obvious. Compared with the control group, the difference was significant (P <0.05). After treatment, the PEF and FEV1 levels in the treatment group were significantly increased (P <0.05), but there was no significant change in the PEF and FEV1 levels in the control group after treatment (P> 0.05). No serious adverse reactions were found in the two groups during the treatment. Adverse reactions There was no difference in incidence between the two groups (P> 0.05), but two patients in the control group developed respiratory infections. Conclusion MTX combined with BCG-PSN treatment of hormone-dependent asthma reliable, less adverse reactions, better than MTX alone, is a safe and effective treatment.